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ATAS PENGETAHUAN, KESEDARAN, PELAPORAN KESAN MUDARAT 
UBAT DAN KOMUNIKASI KESELAMATAN UBAT 
 
  
ABSTRAK 
       
  
Konsep farmakovigilans di Nepal adalah baru.  Kajian ini menilai corak kesan mudarat 
ubat yang dilaporkan ke pusat farmakovigilans di kawasan barat Nepal, dan menilai 
pengetahuan, tingkah laku dan praktis profesional penjagaan kesihatan di Manipal 
Teaching Hospital (MTH) terhadap keselamatan ubat.  Kajian ini juga fokus kepada 
menilai modul pendidikan farmakovigilans untuk ahli farmasi komuniti, dan pelajar 
perubatan, farmasi dan kejururawatan dan menilai komunikasi keselamatan ubat yang 
dihasilkan oleh pusat farmakovigilans. Laporan kesan mudarat ubat yang diterima oleh 
pusat tersebut dalam tempoh 14 September, 2004 sehingga 13 September, 2008 telah 
dinilai.  Pengetahuan, tingkah laku dan praktis profesional kesihatan dari MTH dan ahli 
farmasi komuniti dari kawasan Nepal barat telah dinilai menggunakan dua soal selidik 
yang telah diuji serta berbeza dengan nilai Cronbach alpha 0.72 dan 0.61, setiap satu. 
Tiga puluh ahli farmasi komuniti dengan skor pengetahuan, tingkah laku dan praktis yang 
tinggi telah dilatih dalam aspek farmakovigilans dan telah mencatatkan penambahbaikan 
skor.  Maklum balas mereka berkaitan dengan latihan telah diperolehi menggunakan soal 
selidik dengan skala jenis Likert.  Modul-modul pendidikan telah dibangunkan untuk 
pelajar farmasi, perubatan dan kejururawatan dan dinilai dengan membandingkan skor 
pengetahuan, tingkah laku dan praktis pelajar sebelum dan selepas intervensi dan maklum 
balas terhadap sesi tersebut. Komunikasi keselamatan ubat yang dihasilkan dalam tempoh 
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14 September, 2004 sehingga 13 September, 2008 telah dinilai.  Daripada sejumlah 266 
kesan mudarat ubat yang telah diterima, 153 (57.7%) adalah daripada individu 
perempuan.  Peratusan kesan mudarat ubat yang tinggi (22.2%) adalah disebabkan oleh 
antibiotik. Nilai awal skor pengetahuan, tingkah laku dan praktis adalah 38.82 + 3.75 
untuk jururawat (n=46), 40.06 ± 3.51 untuk doktor (n=29) dan 38.92 ± 4.83 untuk ahli 
farmasi (n=14); skor maksimum adalah 50.  Di antara 108 ahli farmasi komuniti yang 
terlibat, 78.7% (n=85) adalah lelaki.  Nilai min + sd skor keseluruhan bagi pengetahuan, 
tingkah laku dan praktis adalah 31.48  2.25 (skor maksimum adalah 40).  Daripada 71 
kesan mudarat ubat yang dilaporkan oleh mereka, 42.0% (n=37) adalah berkaitan 
antibiotik/antibakterial. Nilai median (julat interkuartail) bagi skor maklum balas adalah 
79.0 (73.5–81.0); skor maksimum adalah 100.  Kesemua 124 pelajar farmasi, 116 pelajar 
jururawat dan 229 pelajar perubatan telah terlibat dalam kajian ini.  Nilai median awal 
(julat interkuartail) skor total adalah 39.0 (37.0-41.0) untuk farmasi (skor maksimum 
adalah 50); 32.5 (31.0-34.0) untuk jururawat (skor maksimum adalah 40) dan 31.0 (29.0-
33.0) untuk pelajar perubatan (skor maksimum adalah 38).  Selepas intervensi, skor 
mereka menjadi lebih baik.  Nilai median (julat interkuartail) skor maklum balas adalah 
86.0 (81.5-90.0), 85.0 (80.8-88.3) dan 83.0 (78.0- 87.0) untuk pelajar farmasi, jururawat 
dan perubatan, setiap satu; skor maksimum adalah 100.  Di antara 18 laporan kes yang 
telah diterbitkan, oleh pusat farmakovigilans kawasan Nepal barat kebanyakannya 
mengikuti garis panduan International Society of Pharmacovigilance/International 
Society of Pharmaepidemiology.  Kesimpulannya, aktiviti farmakovigilans di kawasan 
Nepal barat adalah berjaya dan keperluan aktiviti perlu diperteguhkan dan 
kesinambungan terjamin.        
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PHARMACOVIGILANCE STUDIES INVOLVING HEALTHCARE 
PROFESSIONALS AND STUDENTS IN NEPAL:  IMPACT ASSESSMENT ON 
KNOWLEDGE, AWARENESS, ADVERSE DRUG REACTIONS REPORTING 
AND DRUG SAFETY COMMUNICATIONS 
  
    
ABSTRACT        
  
The concept of pharmacovigilance is new in Nepal. The present study analyzed the 
pattern and cost of pharmacotherapy of Adverse Drug Reactions (ADRs) reported to the 
western regional pharmacovigilance center at Nepal, and evaluated the Knowledge, 
Attitude and Practices (KAPs) of healthcare professionals in Manipal Teaching Hospital 
(MTH) towards drug safety. It also aimed at evaluating pharmacovigilance education 
modules for community pharmacy practitioners, medical, pharmacy and nursing students 
and analyzed the drug safety communications produced by the western regional 
pharmacovigilance center. ADR reports received and the drug safety communications 
produced by the center from 14th September 2004 till 13th September 2008 were 
analyzed. KAP of the healthcare professionals from MTH and community pharmacy 
practitioners from Pokhara valley, western Nepal were evaluated using two different 
pretested questionnaires with Cronbach alpha of 0.72 and 0.61, respectively. Thirty 
community pharmacy practitioners with high KAP scores were trained in 
pharmacovigilance and the KAP improvements were noted. Their feedback on the 
training was obtained using a Likert-type scale questionnaire. Educational modules were 
developed for pharmacy, medical and nursing students and evaluated by comparing the 
students’ knowledge and perception scores prior and following interventions and their 
feedback on the sessions. Of the total 266 ADRs received, 153 (57.7%) were reported 
from females. Antibiotics caused the highest percentage (22.2%) of ADRs. The baseline 
 xxv
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KAP scores were 35.8±3.7 for nurses (n=46), 40.0±3.5 for doctors (n=29) and 38.9±4.8 
for pharmacists (n=14); the maximum possible score was 50. Among the 108 community 
pharmacy practitioners enrolled, 78.7% (n=85) were males. The meansd baseline KAP 
scores was 31.42.2 (maximum possible score was 40). Of the 71 ADRs reported by 
them, antibiotics/antibacterials accounted for 42.0% (n=37) of the ADRs. The median 
(interquartile range) feedback score was 79.0 (73.5-81.0); maximum possible score was 
100.  Altogether, 124 pharmacy, 116 nursing and 229 medical students were enrolled. 
The baseline median (interquartile range) of the total score was 39.0 (37.0-41.0) for 
pharmacy (maximum possible score was 50); 32.5 (31.0-34.0) for nursing (maximum 
possible score was 40) and 31.0 (29.0-33.0) for medical students (maximum possible 
score was 38). Upon educational intervention, their scores improved. The median 
(interquartile range) feedback scores were 86 (81.5-90.0), 85.0 (80.7-88.2) and 83 (78.0-
87.0) for pharmacy, nursing and medical students, respectively; the minimum possible 
score was 50 and the maximum possible score was 100.  Among the 18 case reports 
published by the pharmacovigilance center, a majority followed the International Society 
of Pharmacovigilance/International Society of Pharmaepidemiology guidelines. In 
conclusion, the pharmacovigilance activity in western Nepal is successful and needs to be 
strengthened and sustained.                       
        
    
   
CHAPTER ONE 
GENERAL INTRODUCTION 
 
1.1 Background                                     
Although medicines are very vital in ameliorating disease conditions, often they 
are associated with certain risks.  Adverse Drug Reactions (ADRs) are one of the major 
risk factors associated with the use of medicines, ranging from a mild skin rash to death. 
The World Health Organization (WHO) defines an ADR as ‘a response to a drug which 
is  noxious and unintended, and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease or for the modification of physiological 
function’ (Lee and Thomas, 2003). One of the simplest means of classifying ADRs is 
proposed by Rawlins and Thompson (Rawlins and Thompson, 1977). According to this 
classification, ADRs are classified into ‘type-A’ and ‘type-B’ reactions.  Type-A 
reactions include normal and augmented response to drugs and are dose dependent. 
These reactions are usually predictable and are due to the known pharmacology of drug 
and thus considered to be preventable. The incidence of type-A reactions is high and 
they are responsible for considerable morbidity. Reducing the dosage or changing the 
therapy can overcome this type of reactions. Simple examples for type-A reactions are 
bradycardia with beta adrenoreceptor blockers and bleeding with anticoagulants. Type-
B reactions are unrelated to the known pharmacological action of the drug and are often 
caused by immunological and pharmacogenetic mechanisms. These reactions are 
generally unrelated to dosage and, although comparatively rare, they often cause serious 
illness and death. They are often not predictable and un-preventable. Examples include 
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malignant hyperthermia caused by anesthetics, acute porphyria and many 
immunological reactions (Rawlins and Thompson, 1977). Certain ADRs do not fit into 
either category and hence it is difficult to decide whether certain reactions are type-A or 
type-B. According to this classification, everything that is not a type-A reaction got 
classified as type-B, rendering the latter a highly heterogeneous group.        
An Adverse Drug Event (ADE) is ‘any untoward medical occurrence that may 
present during treatment with a pharmaceutical product but which does not necessarily 
have a causal relationship with this treatment’ (Anon, 2008). An ADE, is characterized 
by the suspicion of a causal relationship between the drug and the occurrence, i.e. 
judged as being at least possibly related to treatment by the reporting or a reviewing 
healthcare professional (Anon, 2008).  ADRs are a cause of significant morbidity and 
mortality, affecting a huge population worldwide. ADRs are responsible for hospital 
admissions, with reported rates ranging from 0.3% to as high as 11%. Overall, the 
incidence of ADR induced hospital admissions accounts for 3% of all medical 
admissions (Lee and Thomas, 2003). In the United States (US) alone, over 77 000 
people are injured or killed each year from ADEs (Classen et al., 1997).     
In addition to their health hazards, ADRs also increase the hospital stay and 
cause huge economic loss. A study from the US demonstrated that an ADE extended 
the hospital stay by nearly two days and increased the cost of hospitalization by about 
US$ 2 000 (Classen et al., 1997).  Another study from Colombia reported the costs 
resulting from medical care of ADRs to be US$ 35 014.92 to US$ 45 680.94 (Tribiño et 
al., 2006). It has been found that the total cost of medicine related morbidity and 
mortality exceeds the cost of medications themselves (Smith, 1993). The cost associated 
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with medicine related morbidity and mortality is exceedingly high in the US, and is 
estimated to range between US$ 30.1 billion and US$ 136.8 billion annually if direct 
and indirect costs are included (Johnson and Bootman, 1996). The limited resources of 
healthcare delivery systems in developing countries are stretched even further by ADR-
related admissions. The economic impact of ADRs is less documented from developing 
countries. However, a recent study from South India identified the total cost incurred in 
managing ADRs to be Indian rupees 76 564 (US$ 1 595) with an average cost of Indian 
Rupees 690 (US$ 15) per ADR (Ramesh et al., 2003).  Although ADRs presents as a 
major problem in the healthcare system, a high percentage of them are preventable if 
adequate measures are taken (Kanjanarat et al., 2003). One of the strategies to minimize 
the occurrence and severity of ADRs is through effective monitoring of ADRs in a 
systematic manner, involving all the key players in medicine use.                 
During the 1960s, in the aftermath of the thalidomide disaster, national 
pharmacovigilance centers were established in several countries around the world 
(Meyboom et al., 1999). This was later strengthened worldwide by the events of 
Subacute Myelo-Optic Neuropathy (SMON) syndrome due to clioquinol (1969), venous 
thromboembolism due to oral contraceptives, oculo-muco-cutaneous syndrome due to 
practolol (1975), blood dyscrasias and Gastrointestinal (GI) bleeding due to Non-
Steroidal Anti- Inflammatory Drugs (NSAIDs) (Edwards and Olsson, 2002).       
 In recent days, the importance of medicine safety monitoring has been felt in 
many countries worldwide. The drug regulatory authorities have taken the initiatives 
and are involved in safety monitoring of medicines. The WHO program was established 
in 1968 as a pilot project with the participation of ten countries initially and later 
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strengthened by many. In the United Kingdom (UK), the United Kingdom’s Medicine 
Control Agency (MCA) and the Committee on Safety of Medicine (CSM) were set up 
in 1964. Similarly, in the US, the Vaccines Adverse Event Reporting System (VAERS) 
was set up in 1990 and co-administered by the Department of Health and Human 
Services (DHHS). Countries like Australia and Canada also established Adverse Drug 
Reactions Advisory Committees (ADRAC) and Canadian Adverse Drug Reaction 
Monitoring programs, respectively (Anon, 2002).  The list of member countries 
increased steadily and as of March 2009, there were 94 member countries in the WHO 
international drug monitoring program (The Global Network for Benefits and Risks in 
Medicinal Products, 2009).        
Nepal is a landlocked country situated between India and China. It encompasses 
a total area of 147 181 square kilometers and an estimated population of 21.1 million. 
Geographically, Nepal is divided into five regions- eastern, central, western, mid- 
western and far-western regions. The capital city, Kathmandu is located in Central 
Nepal. The geography of Nepal varies from the alpine grass lands to mountains. The 
health status of Nepalese people is generally poor. This is reflected in low life 
expectancy at birth of 61 years (2004), high maternal mortality of 281 per 100 000 live 
births (2006), and high infant mortality of 48 per 1000 live births (2005) (Nepal Health 
System Profile, 2007). The government run hospitals usually lack sophisticated 
equipment, qualified manpower and medicines due to which private hospitals are 
preferred. The annual medicine consumption in Nepal is estimated to be over 3 719.3 
million Nepalese rupees (approximately US$ 46 million), with an estimated 28.5% rate 
of increase in consumption every year (Anon, 2006a). Domestic pharmaceutical 
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companies produce only 35.4% of all medicines consumed in the country, the rest, 
64.6% being imported mainly from India (Anon, 2006a). However, in the recent past, 
the situation is changing. Local pharmaceutical companies are attracting a huge amount 
of prescribers in the country and their manufacturing capacity is increasing steadily.    
The use of allopathic and ayurvedic medicines in Nepal, their manufacturing, 
importing, exporting, procurement, and sales are regulated at the Nepal Department of 
Drug Administration (DDA) which is the national drug controlling authority. The 
manufacturing companies require permission from the DDA in order to manufacture 
medicines in Nepal. For marketing medicinal products in Nepal by foreign companies, 
all the products should be registered with the DDA. The DDA registers medicinal 
products based on their safety, efficacy, quality and affordability.        
 
1.2 Problem statement 
Safety and efficacy studies conducted prior to the introduction of a new 
medicine (clinical trials) into the market are designed to identify any ADRs that may 
occur with the medicines. However, only a relatively limited number of patients are 
evaluated in these studies. Moreover, the exclusion criteria of many of these studies 
eliminated patients with multiple disease states and other contributing factors to ADRs. 
In addition, special patient populations such as pediatric, geriatric and pregnant ladies 
are not studied well in the clinical trials. Besides, most of these studies are of short term 
and are thus, unable to recognize any ADR associated with long term use (Alastair, 
2001). Therefore, it is essential to monitor the ADRs of medicines even after once they 
are launched in the market.                
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  In the past, pharmacovigilance was considered as a mere adverse drug 
monitoring or drug surveillance activity. But, nowadays it is considered as the quality 
control system of the society (Olsson, 2001). Its broader aim is to check if medicines 
fulfill their intended role in alleviating human suffering, and reducing disease related 
economic loss, with the best acceptable patient safety. The ultimate aim of 
pharmacovigilance is to attain safe and rational use of medicines once they are released 
for general use in the society. The most important outcome of pharmacovigilance is the 
prevention of negative consequences of pharmacotherapy (Olsson, 2001). 
Pharmacovigilance is defined as the ‘science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other medicine 
related problems’ (Olsson, 2001). Even though pharmacovigilance is considered useful, 
many developing countries have not been successful in establishing a stringent 
pharmacovigilance system in their countries (Couper, 2006).       
  Several guidelines have been developed regarding the use of medicines in the 
past, by the medicine regulatory authorities, professional bodies and voluntary 
organizations including the Joint Commission on the Accreditation of the Healthcare 
Organization (JCAHO), American Society of Health System Pharmacists (Rollins, 
2000), ERICE declaration (Edwards, 2000), and Berlin declaration by International 
Society of Drug Bulletins (ISDB) (ISDB EU, 2005).  In spite of several strategies being 
implemented worldwide, the under-reporting of ADRs is a major problem (Alvarez-
Requejo et al., 1998). According to Rogers et al, many times healthcare workers either 
do not understand the importance of ADR reporting or do not find the current system 
convenient to report ADRs (Rogers et al., 1988).        
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Spontaneous reporting schemes for suspected ADRs have been a major source 
of information in pharmacovigilance (Meyboom et al., 2002). Spontaneous reporting 
can prevent the development of new medicine tragedies and can improve the safety 
labeling of many effective pharmaceutical products (Anon, 2002; Hartigan-Go, 2001).  
Hence, healthcare professionals should report ADRs as a part of their professional 
responsibility. They should be knowledgeable about the ADR reporting systems in their 
region and country and should be aware of the importance of reporting ADRs. 
Developed countries have incorporated pharmacovigilance teaching into medical and 
pharmacy curricula (Zenut et al., 1998; Cox et al., 2004). However, in developing 
countries pharmacovigilance has not found a place in most medical, nursing and 
pharmacy schools. ADRs are only included as a topic in didactic lectures and the 
practical aspects is lacking (Shankar et al, 2006a).                
At present, there are four regional pharmacovigilance centers in Nepal. These 
centers are located at Manipal Teaching Hospital (MTH) in Pokhara, Tribhuvan 
University Teaching Hospital (TUTH) in Kathmandu, Nepal Medical College Hospital 
(NMCH) in Kathmandu and KIST Medical College in Lalitpur. These regional centers 
report ADRs to the national centre through a web based system for ADR management 
called ‘VigiFlow’.  The initial two centers were started in 2004 and 2006, respectively 
and the third and the fourth ones were established in 2008. These centers are all hospital 
based and are involved in collecting the ADRs occurring in the hospitals in which they 
are affiliated. Thus, there was no established system to collect the ADRs occurring in 
the community settings.    
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The success of a pharmacovigilance program depends largely upon the 
communication of the medicine safety related information generated through the 
program. But, in developing countries, there are only limited pharmacovigilance 
programs in place and often the little information available on medicine safety issues is 
not communicated adequately. Specifically, in Nepal, there is very little information 
available on medicine safety. The DDA publishes a quarterly bulletin, the Drug Bulletin 
of Nepal (DBN) that focuses on medicine safety issues. But, the information presented 
are from developed countries and hence, difficult to generalize for the local population.   
  
1.3 Rationale of the study  
In Nepal, nearly 65% of the medicines are imported from foreign countries and 
only 35% are manufactured in Nepal (Anon, 2006a). Prior to marketing a medicine in 
Nepal, the DDA evaluates it thoroughly based on the available literatures and then 
approves it. The DDA was established in 1979 after promulgation of the ‘Drug Act 
1978’. The main objective of the act is to assure safety, efficacy and quality of 
medicines available in the Nepalese market. As per the Drug Act 1978, ‘every drug 
shall have to be safe for the use of the people, efficacious and of standard quality’ 
(Anon, 1978). In the above view, the DDA in the past has banned several medicines to 
ensure medicine safety in Nepal. Some of the examples include amidopyrin, phenacetin, 
clioquinol, analgin (metamizole) along with several other harmful irrational 
combinations. Also, registration of products like gatifloxacin and Cyclooxygenase-2 
(COX-2) inhibitors were denied due to safety concerns (Thapa, 2006). These decisions 
were taken by the DDA based on the information available in the literature since no 
 8
system existed to monitor ADRs within the country. Although, these regulatory 
mechanisms were in place, they were restricted only to limited medicines and the 
decision on ban/denial of registration of these medicines were made based on the 
existing literature available from developed countries.            
Out of 75 districts in Nepal, about two-thirds are located in hilly regions and 
mountains and the remaining in plains (called as ‘terai’). The climatic conditions in the 
country vary from season to season and from place to place. This variation in climate is 
known to be a predisposing factor for the occurrence of ADRs (Subish et al., 2005). 
Moreover, there are several races of people having different cultural and social beliefs. 
The use of alternative medicines (for example ayurveda and siddha) is common in 
Nepal, which may interact with allopathic medicines and predispose to ADRs. The 
manufacturing facilities in Nepal are limited and thus, majority of the medicines used in 
Nepal are manufactured in foreign countries (especially India). The nature and safety of 
the excipients used in these formulations are unknown. Moreover, the number of 
medicinal preparations available in the Nepalese market is high (7299 in the year 
2004/05 and 7237 in 2005/06) and thus, people are exposed to more items and varieties 
of medicines (Subish et al., 2007). The genetic makeup of the Nepalese population may 
vary and hence predispose to ADRs. There are no mandatory requirements for clinical 
trials on the Nepalese population prior to approval of a medicine in Nepal. Hence, the 
risk of occurrence of ADRs can be very high and is infact unknown.               
The infrastructure in Nepal is limited and the country has a poor development. 
The doctor to population ratio is very poor (1:23 000) and the utilization of government 
health services averages only 0.2 visits per person per year. Retail pharmacies are more 
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in number than the health posts/ health centers in the country by a ratio of 4:1 and drug 
retailers are often the only sources to modern medicines for the rural population. In 
some cases, they are the only source of healthcare outside the home thus making a lot of 
people to rely upon them for the healthcare needs (Kafle et al., 1992). This makes the 
people dependent on self-medication (Kafle et al., 1996) with the medicines obtained 
from drug retailers. Self-medication may contribute to ADRs either by the medicine 
itself or by causing an interaction with a prescription medicine. Moreover, the literacy 
ratio in Nepal is also poor (total adult literacy rate, 2000-2005 is only 49 %) (Anon, 
2006b). All these problems collectively increase the risk for ADRs in the community 
settings of Nepal.         
In developing countries, quality of medicines is a major concern (Jayasuriya, 
1991). By encouraging ADR reporting, the quality of medicines can be predicted. For 
example, substandard or counterfeit medicines may cause ADRs suggesting their poor 
quality. A pharmacovigilance program can also identify the safety of medicines used in 
public health programs such as the vaccines, antitubercular drugs and antiretroviral 
drugs. Moreover, if an indigenous pharmacovigilance program is developed in Nepal, it 
will be helpful in developing the ADR profile of medicines (ADR database) in the local 
population.     
Though, the role of healthcare professionals is important, there is only a limited 
focus on teaching pharmacovigilance to the healthcare students in Nepal.  Many of the 
institutions in Nepal also lack competency in terms of staffing, infrastructure, and 
facilities to teach modern pharmacotherapy. In contrast to the existing education system 
in Nepal, the Manipal College of Medical Sciences (MCOMS) has taken several 
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initiatives to teach rational pharmacotherapy to their medical students. Pharmacology is 
taught using a combination of didactic lectures and problem-stimulated learning 
sessions. This department also runs a Drug Information Center (DIC) and a 
pharmacovigilance center in the Manipal Teaching Hospital (MTH), the teaching 
hospital attached to the college (Shankar, 2006c).      
             Since, there is no mandatory clinical trial that needs to be done in the local 
population prior to approval of a new medicine in the country, institutional based 
pharmacovigilance programs are the key for ensuring medicine safety. One of the 
objectives of the regional pharmacovigilance center at the western Nepal is to 
communicate medicine safety issues. The regional pharmacovigilance center has taken 
several initiatives to communicate the medicine safety related issues with the objective 
of ensuring medicine safety in the country.  All the ADR reports from the center are 
reported to the WHO global ADR database through the ‘VigiFlow’ online program. 
Periodic evaluation of the communication produced on medicine safety can be 
beneficial in better dissemination of the existing medicine safety information.     
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1.4 Research questions    
The overall study had the following research questions: 
  
1. Are the adverse drug reaction patterns in western Nepal similar to the patterns 
documented in the literature? 
 
2. What is the knowledge, attitude and practice level of the healthcare professionals in 
western Nepal towards adverse drug reactions and pharmacovigilance? 
  
3. Can educational intervention improve adverse drug reaction reporting by the 
community pharmacy practititoners in western Nepal? 
 
4. Can educational intervention improve the knowledge, attitude and practice of the 
medical, nursing and pharmacy students in western Nepal? 
 
5. Do the scientific communications on medicine safety produced by the regional 
pharmacovigilance center in western Nepal comply with international standards?   
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1.5 Study objectives  
The whole study was conducted based on the following objectives:  
 
1. To analyze the pattern and cost of pharmacotherapy of the adverse drug reactions 
reported to the regional pharmacovigilance center in western Nepal, 
  
2. To study the knowledge, attitude and practices of the healthcare professionals in 
Western Nepal towards adverse drug reactions and pharmacovigilance,   
 
3. To develop and evaluate a community based pharmacovigilance educational program 
in western Nepal,     
 
4. To develop and evaluate the impact of education modules on knowledge and 
perception among the medical, pharmacy and nursing students in western Nepal, and     
 
5. To evaluate the pattern of scientific communications on medicine safety produced by 
the regional pharmacovigilance center in western Nepal.          
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1. 6 Significance of the study  
In Nepal, as such there was no standard system which existed to ensure 
medicine safety until 2004. Considering its importance, the DIC at MTH, a tertiary care 
teaching hospital in Western region of Nepal has decided to start a spontaneous ADR 
reporting program. The program has been established in September 2004 with a 
pharmacovigilance center, as a unit of the DIC of the hospital that has been functioning 
since November 2003. The Uppsala Monitoring Center (UMC), the WHO collaborating 
center for international drug monitoring provided the technical support by providing 
literature and booklets necessary to begin the program. The DDA has established 
regional centers which report the ADRs to the national center through the ‘VigiFlow’ 
online program which are then submitted to the WHO global ADR database. The DDA 
acts as the national center for pharmacovigilance activities. As of March 2009, more 
than 300 ADR reports were sent to the national pharmacovigilance center from the 
various pharmacovigilance centers. In collaboration with UMC, Nepal has also been 
able to contribute to the global database by sharing information with UMC. This 
program though in its initial phase, has given a good platform to promote the culture of 
ADR reporting among the healthcare professionals and to be vigilant. DDA has been 
working towards addition of more teaching hospitals for ADR reporting so as to 
strengthen the pharmacovigilance program. The revised National Medicine Policy 2009 
(Anon, 2009) of Nepal has also recognized the need for a pharmacovigilance program in 
Nepal and has aimed for implementation of the programme for effective post-marketing 
surveillance and ADR reporting to ensure safe use of medicines in the country.        
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Ensuring safe use of medicines is a collective responsibility of the healthcare 
team, including the doctors, nurses, pharmacists and other supporting staffs. One of the 
important means of ensuring medicine safety is reporting of ADRs by the healthcare 
professionals. Pharmacists being knowledgeable in medicine related aspects have got an 
important role in ensuring medicine safety. The involvement of pharmacists in 
pharmacovigilance programs is considered vital (van Grootheest et al., 2002; van 
Grootheest et al., 2004; van Grootheest et al., 2005). However, contrary to their vital 
role, studies from the developed countries have acknowledged either a poor knowledge 
(Toklu et al., 2008) or less experience among the pharmacists regarding ADR reporting 
(Granas et al., 2007). Researchers suggest the need for education of pharmacists on 
pharmacovigilance (Green et al., 2001). One of the better ways to do this is by 
educating when they are students. The education provided for the medical and 
pharmacy students even in developed countries like the United Kingdom (UK) was 
found to be inadequate. A study found that both medicine and pharmacy courses 
differed substantially in teaching about the Yellow Card Scheme and ADRs (Cox et al., 
2004). Authors found a huge scope for increased involvement of the medicines and 
healthcare products regulatory agency in undergraduate education (Cox et al., 2004). 
The present study also noted a similar observation, suggesting huge scope for 
improvements. Nurses, who record signs and symptoms of the patients, play an 
increasingly important role for detection of suspected ADRs (Ulfvarson et al., 2007). A 
recent study from Sweden reported that ADR reporting by nurses could improve the 
overall safety of medicines (Bäckström et al., 2007). The pharmacovigilance center at 
western Nepal was successful in teaching pharmacovigilance to the medical, nursing 
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and pharmacy students in the region. The findings of the present study can be useful for 
researchers in different parts of Nepal and other developing countries in educating their 
students in the area of pharmacovigilance.                     
Qualified doctors in Nepal are less willing to set up practice in the villages and 
as a result, rural patients often rely upon traditional healthcare practitioners for their 
healthcare needs (Sharma et al., 2001). In addition, due to remoteness, poor 
socioeconomic status, high cost of modern medicines and non-availability of doctors in 
rural areas, it has been difficult to access modern healthcare in Nepal. This leaves 
people dependent on self-medication which is known to cause ADRs.  Retail pharmacies 
are the primary point of contact with the healthcare system for the rural and remote 
population. Although, there are four regional pharmacovigilance centers in operation, 
the activities are much focused on the hospital settings. ADRs following self-
medication and ADRs occurring outside the hospital remain unreported. Hence, the 
regional pharmacovigilance center of western Nepal has started a community-based 
pharmacovigilance program in the year 2008 in which the community pharmacy 
practitioners report the ADRs. During the initial six months of establishment of the 
program, the center received more than 70 ADR reports from the community pharmacy 
practitioners of western Nepal.            
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CHAPTER TWO 
EVALUATION OF THE PATTERN AND COST OF PHARMACOTHERAPY 
OF ADVERSE DRUG REACTIONS   
  
2.1 Introduction    
This part of the chapter provides an overview on the background, problem 
statement, literature review, rationale and objectives of the study.  
  
2.1.1 Background   
With the increase in use of medicines, the incidence of Adverse Drug Reactions 
(ADRs) is increasing rapidly. ADRs are considered to be associated with significant 
morbidity, mortality and huge economic impact (Johnson and Bootman, 1996). Safety 
and efficacy studies conducted prior to the introduction of a new medicine into the 
market try to identify any ADRs that may occur with the medicines. However, only a 
relatively limited number of patients are evaluated in these studies (Striker and Psaty, 
2004). Exclusion criteria of many of these studies eliminate patients with multiple 
disease states or other contributing factors to ADRs. Moreover, special patient 
population such as pediatrics and geriatrics are not studied well in the clinical trials. 
Also, most of the studies are of short term medicine use and thus eliminate the ability to 
recognize the ADRs associated with long term use (Alastair, 2001). Thus, many ADRs 
escapes from the early safety studies done by the manufacturer (phase I through III) and 
thus making it necessary to monitor the ADRs even after the medicines are being 
launched in the market (Stricker and Psaty, 2004).                      
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2.1.2 Problem statement 
 In developed countries, the concept of ADR monitoring is well developed and 
plays an active role in ensuring safe use of medicines including withdrawal of 
potentially harmful medicines from the market.  On the other hand, in developing 
countries like Nepal, the regulatory mechanisms monitoring medicine safety is very 
weak. In Nepal, irrational use of medicines is very much in evidence, some examples 
are polypharmacy, use of expired medicines, irrational combination drugs, overuse of 
antibiotics, vitamins and herbal remedies, brand prescribing, retail pharmacists 
prescribing and unethical medicine dispensing (Blum, 2002). Such irrational practices, 
combined with lack of patient information on proper handling and uses of medicines 
can lead to pharmaceutical wastage as well as other serious consequences like ADRs 
and drug interactions (Blum, 2002). Moreover, there is no mandatory rule for the 
pharmaceutical companies to produce medicine safety data prior to marketing 
medicines. Medicine safety is one of the most neglected areas in Nepal, although there 
are few reports available in the literature (Shakya et al., 2004; Shrestha et al., 2006).          
 
2.1.3 Literature review      
  ADRs are unwanted or unintended effects of medicines which occur during their 
normal therapeutic use. Safe use of medicines is an important issue for prescribers, 
pharmacists, nurses, regulatory authorities, the pharmaceutical industry, patients and the 
public. Although, prescribers aim to use medicines that help patients and do no harm, 
no medicine is administered without risks. Minimizing the occurrence of ADRs is an 
important challenge in medicine use, and helps to improve patient care. 
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2.1.3.1 Literature from developed countries      
A study from Italy analyzed the data from the national spontaneous reporting 
system and described the types and patterns of fatal ADRs reported to the national ADR 
monitoring system (Leone et al., 2008). The pharmacovigilance database maintained by 
the Italian Medicines Agency was reviewed for all the case reports from 1st January 
2001 till 31st December 2006. Among the reports, the ones with a fatal outcome were 
analyzed. Authors found 1.66% of the total ADRs to have a fatal outcome. A highest 
percentage of the fatal ADRs were related to ‘systemic anti-infective’ drug class 
accounting for 21.9% of the total fatal ADRs. Ceftriaxone, ticlopidine and nimesulide 
were the individual drugs responsible for a highest incidence of fatal ADRs. The study 
also notified certain lacunae in the medicine prescribing by the physicians and 
recommended the need for continuing clinical pharmacology training.                 
     Wester et al., (2007) described the pattern of spontaneously reported fatal ADRs 
documented at the national spontaneous reporting system in Sweden. All the suspected 
fatal ADRs reported to the Swedish Medicine Agency during the study period (1st 
January 1995 to 31st December 2004) were evaluated for the types of drugs 
administered, the types of ADRs, causality assessment, and the patient demographic 
parameters, sex and age. A total of 3.1% of the ADRs were found to be fatal. The most 
common fatal ADRs were caused by hemorrhage (60.9%) and warfarin was responsible 
for maximum number of hemorrhages. Sudden death was seen in 3.8% of the total cases 
and the drugs responsible for sudden death were clozapine, citalopram and 
propoxyphene. In this study, considering the amount of anticipated under-reporting, 
authors claimed ADRs to be one among the top 12 causes of death in Sweden.        
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Pirmohamed et al., (2004) evaluated the burden of ADRs in England through a 
6-month prospective analysis of hospital admissions in United Kingdom (UK). The 
study was conducted in two hospitals in United Kingdom (UK), both together serving 
for a total population of 630 000. The patients aged less than 16 years and women with 
gynecological problems were excluded from the study in order to maintain uniformity 
between the study populations. Altogether, 18 820 hospitalized patients were assessed 
for the cause of hospitalization. Among these patients, 1225 (6.5%) were admitted due 
to ADRs. ADRs were more commonly seen in patients belonging to a higher age group.  
Authors found, 72% of the ADRs were ‘avoidable’ if proper precautions were taken. In 
this study, 16.6% of the ADRs were caused due to drug-drug interactions. The cost of 
ADRs in this study accounted for 466 million Euros (Approximately US$ 659.3 
million) to the National Health Service (NHS) of the UK.  The major strength of this 
study is that it is a prospective study thus allowing a detail workout of the cases implied 
with ADRs.                 
van der Hooft et al., (2006) conducted a nationwide survey on drug-related 
hospitalizations in Netherlands. Authors retrieved the hospital discharge records 
through a nationwide computer database. A total of 668 714 patients admitted in the 
hospitals throughout country in the year 2001 with an acute, non-planned hospital 
admissions were included. Of these total hospitalizations, 12 249 were related to ADRs 
accounting for an incidence of 1.83% of all acute, non-planned hospitalizations in the 
country. Moreover, 6 % (n=734) of the patients admitted with ADRs died during the 
hospitalization. The mean duration of stay in the hospital was 12.5 days for patients 
with an ADR in comparison with 10 days in other cases of acute hospitalizations. This 
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study also identified a significant level of under-reporting in Netherlands. As per the 
study findings, only 59 (approximately 1%) of the total 6 209 hospital admissions were 
actually reported to the national pharmacovigilance program spontaneously.             
  Alexopoulou et al., (2008) prospectively evaluated the pattern of ADR related 
hospital admissions in an internal medicine department in Greece. Authors evaluated all 
hospital admissions occurring at the internal medicine department for a 6-months 
period. During the study period, there were 548 admissions, among which 70 were 
related to ADRs (12.8%). These 70 patients experienced 74 ADRs. The most commonly 
seen ADR was hemorrhage (37.3%) followed by metabolic complications caused by 
oral hypoglycemic agents (10.8%). Of the total ADRs, 89.2% were of ‘type-A 
reactions’ and the remaining were ‘type-B reactions’ suggesting a high percentage to be 
pharmacologically related and hence avoidable. A high percentage (81.4%) of the 
ADRs evaluated in this study was of ‘moderate’ severity. In this study, authors noted 
polypharmacy to be a predisposing factor for ADRs.        
 Moore et al., (1998) prospectively assessed the pattern of ADRs leading to 
hospitalization or prolonging hospitalization in France. All the patients getting admitted 
to a 29-bedded internal medicine ward of a general hospital were prospectively 
followed for 6 months by a physician. The physician everyday followed the patients for 
the presence of serious ADRs. All the cases known to have a serious ADR were further 
reviewed by a specialist in drug induced illness. Over the period of 6 months, 31 
patients, among 329 had ADRs. Among these 31 patients, ADRs were responsible for 
hospitalization in 10 patients and in the remaining 21 patients, the ADRs occurred 
during their hospital stay.  Among the 31 patients, four of them died due to the ADRs. 
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All the 10 patients presenting with ADRs (100%) and 14 of 21 patients (66.0%) who 
developed ADRs in the hospital had ‘type-A’ ADRs suggesting them to be 
pharmacologically related to the suspected drug (s).     
   Another study from France evaluated the prevalence, incidence and 
preventability of ADRs occurring in hospital and ADRs that lead to hospitalization. 
Authors also evaluated the direct costs of these ADRs (Lagnaoui et al., 2000).  Authors 
prospectively followed all the patients getting admitted to the internal medicine ward of 
a hospital for four months.  A total of 444 patients were admitted during the study 
period. Among these patients, 116 (26.1%) experienced an ADR. In 32 patients (7%), 
ADR was the reason for hospitalization. It was seen that 64.7% (n=101; total 156 
ADRs) of the ADRs were related to the pharmacological properties of the drugs (type-A 
reactions). Among the 32 ADRs that caused hospitalization, the most common ones 
were neurological disorders, hypoglycemia, autoimmune diseases and hematological 
disorders. In this study, the mean cost an ADR related to hospitalization was Euro 2721 
(approximately US$ 3850). Authors found 80% of the ADRs occurred to be 
‘preventable’.           
A study from Belgium by Somers et al., (2003) evaluated the ADRs occurring in 
a geriatric ward of a university hospital and compared the ADRs reported spontaneously 
by the physicians and nurses with the ADRs identified by the pharmacists through 
direct patient interview. During the study period (8 months), 168 patients were admitted 
to this 27 bedded geriatric ward. In this period, 12 ADR reports were received through 
the spontaneous reporting (physicians and nurses). Of these ADRs, four were related to 
cardiovascular drugs followed by centrally acting drugs in another four cases. Among 
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these ADRs, six were classified as ‘serious’. But, during the direct patient interview of 
56 patients, by pharmacists, there were 32 ADRs from 23 patients. Of these 32 ADRs, 
10 were caused by cardiovascular drugs, followed by drugs acting on respiratory system 
(n=7) and centrally acting drugs (n=5). Authors suggested a combination of both 
spontaneous reporting by physicians and nurses, and patient interview by pharmacists to 
be a useful method for successful ADR monitoring program.  
  The above literature revealed ADRs to be a common cause of hospitalization 
and death in the developed world. In these studies, the incidence of hospitalization due 
to ADRs varied from 6.5% in UK (Pirmohamed et al., 2004) and 7% in France 
(Lagnaoui et al., 2000). The drug class responsible for ADR also varied from 
antibacterials to cardiovascular drugs depending upon the study setting and the drug 
utilization pattern. The mortality rates due to ADRs ranged from 1.66% in Italy (Leone, 
2008), to 3.8% in Sweden (Wester et al., 2007), and 6% in Netherlands (Van der hooft 
et al., 2006), suggesting ADRs to be a major cause for mortality in these countries. The 
ADRs responsible for mortality also varied among studies and in one study, hemorrhage 
being responsible for 60.9% of the fatal ADRs (Wester et al., 2007).    
In most of these studies, majority of the ADRs were related to the 
pharmacological properties of the suspected drug (type-A) and a high percentage of 
them were considered ‘preventable’, suggesting preventable ADRs to be common even 
in developed countries. In one of the studies, authors noted polypharmacy to be a 
predisposing factor for the occurrence of ADRs (Alexopoulou et al., 2008). Among 
these studies, two of them reported the economic impact of the ADRs.  One study 
reported, the total cost of the ADRs to be approximately US$ 659.3 million for the 
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national health service of the UK (Pirmohamed et al., 2004) and another calculated the 
mean cost an ADR related to hospitalization as approximately US$ 3850. These 
findings suggest a huge economic loss due to ADRs in developed world. It is evident 
that proper monitoring of ADRs targeted at early detection and prevention can help in 
minimizing significant morbidity, mortality and economic losses.  
 
 2.1.3.2 Literature from developing countries  
Pourseyed et al., (2009) from Iran evaluated the nature and pattern of ADRs in 
an internal medicine department. Authors prospectively studied all the patients getting 
admitted to the 35-bedded internal medicine ward of a general hospital in the capital 
city, Tehran, for four and half months. Among the 400 admissions that occurred during 
the study period, 47 (11.75%) cases experienced at least one ADR. In seven (1.75%) of 
the cases, ADR were responsible for hospitalization and in the remaining 40 (10%) 
cases, ADRs occurred during the hospital stay.  The mean ± sd age of the patients 
experiencing ADRs was 54.29± 2.08 years. The Gastrointestinal (GI) (44.3%) related 
ADRs were seen in higher number of cases followed by psychiatric disorders (11.4%) 
and skin disorders (11.4%).  Nausea and vomiting were the most common 
manifestations of the ADRs accounting for 32.2% of the total manifestations. Half 
(50%) of the ADRs were categorized as ‘preventable’ type of reactions. The individual 
drug responsible for more number of ADRs was fluorouracil causing 15 ADRs, 
followed by cisplatin causing 14 ADRs. This study was conducted in internal medicine 
ward that also treated cancer patients and thus, the findings cannot be generalized to a 
mere internal medicine ward.               
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Another prospective, observational study from South Africa (Mehta et al., 2008) 
compared the pattern of ADRs, both occurring in and reported to two medical wards of 
a hospital. This hospital is a 300-bedded secondary care hospital that serves for a 
community with a higher incidence of Human Immunodeficiency Virus (HIV) infected 
patients. The clinical pharmacologists evaluated the patients for presence of ADRs. 
Totally, 665 patients were studied, among which 93 (14%) had an ADR. Of these 93 
patients, 52 were admitted due to an ADR, 38 developed an ADR during the hospital 
stay and three patients had both ADR in the hospital plus had an ADR prior to hospital 
admission. In general, the patients who got admitted due to an ADR had a higher age 
pattern. Of the ADRs occurring prior to hospitalization, 84% were of type-A reactions. 
The drug category responsible for ADRs in these patients was cardiovascular drugs, 
followed by antiretroviral and oral hypoglycemic agents. Among the ADRs that 
occurred in the hospital, 74.5% were of ‘type-A’, and one third (33.3%) were 
considered ‘preventable’. This study recommended for better drug selection procedures 
and patient monitoring in order to minimize the burden of preventable ADRs.       
Jose and Rao, (2006) analyzed the pattern of ADRs reported to a 
pharmacovigilance center located in a tertiary care teaching hospital in South India. 
Authors also analyzed the outcomes of the ADRs, causality, severity, preventability 
assessments along with the predisposing factors for ADRs. During the one year study 
period (March 2004-February 2005), 408 ADRs were reported from 382 patients. The 
overall incidence of the ADRs was 0.15%.  Authors noted at least one ADR per 1.14% 
of hospitalized patients and 0.012% of the outpatients. A high percentage of the 
reported ADRs were of type-A reactions (72.5%). Skin was the most commonly 
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